K2M Group’s (KTWO) Buy Rating Reaffirmed at Oppenheimer

K2M Group (NASDAQ:KTWO)‘s stock had its “buy” rating reiterated by equities research analysts at Oppenheimer in a report issued on Friday, November 10th. They currently have a $24.00 price objective on the medical device company’s stock. Oppenheimer’s price target points to a potential upside of 23.46% from the stock’s current price.

A number of other equities research analysts also recently weighed in on the stock. Needham & Company LLC reissued a “strong-buy” rating and issued a $27.00 price target (down from $29.00) on shares of K2M Group in a report on Monday, October 9th. They noted that the move was a valuation call. Cowen reaffirmed a “buy” rating and set a $26.00 price objective on shares of K2M Group in a research note on Wednesday, July 19th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $26.00 price objective on shares of K2M Group in a research note on Thursday, July 20th. UBS reaffirmed a “buy” rating and set a $24.00 price objective (down from $26.00) on shares of K2M Group in a research note on Tuesday, October 10th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $28.00 target price on shares of K2M Group in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. K2M Group presently has a consensus rating of “Buy” and a consensus target price of $25.00.

K2M Group (NASDAQ:KTWO) traded down $0.15 during mid-day trading on Friday, reaching $19.44. 420,300 shares of the company traded hands, compared to its average volume of 408,993. K2M Group has a 1-year low of $17.23 and a 1-year high of $25.99. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.06 and a quick ratio of 1.67.

K2M Group (NASDAQ:KTWO) last issued its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.01). K2M Group had a negative net margin of 16.22% and a negative return on equity of 16.02%. The business had revenue of $62.65 million during the quarter, compared to analyst estimates of $62.69 million. During the same period in the previous year, the company posted ($0.19) earnings per share. K2M Group’s revenue was up 5.6% compared to the same quarter last year. analysts anticipate that K2M Group will post -0.86 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. TimesSquare Capital Management LLC boosted its position in shares of K2M Group by 31.5% in the second quarter. TimesSquare Capital Management LLC now owns 2,888,020 shares of the medical device company’s stock valued at $70,352,000 after acquiring an additional 691,000 shares during the period. Cortina Asset Management LLC lifted its position in K2M Group by 5.5% in the third quarter. Cortina Asset Management LLC now owns 1,736,285 shares of the medical device company’s stock worth $36,827,000 after purchasing an additional 90,365 shares during the period. Schroder Investment Management Group lifted its position in K2M Group by 0.9% in the third quarter. Schroder Investment Management Group now owns 1,574,831 shares of the medical device company’s stock worth $32,552,000 after purchasing an additional 14,491 shares during the period. Vanguard Group Inc. lifted its position in K2M Group by 12.4% in the second quarter. Vanguard Group Inc. now owns 1,550,592 shares of the medical device company’s stock worth $37,772,000 after purchasing an additional 171,502 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in K2M Group by 4.9% in the third quarter. JPMorgan Chase & Co. now owns 1,031,404 shares of the medical device company’s stock worth $21,318,000 after purchasing an additional 48,297 shares during the period. 98.22% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first posted by BBNS and is the property of of BBNS. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://baseballnewssource.com/markets/k2m-group-holdings-inc-ktwo-receives-buy-rating-from-oppenheimer-holdings-inc/1775616.html.

K2M Group Company Profile

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Analyst Recommendations for K2M Group (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan


Leave a Reply

 
© 2006-2017 BBNS.